| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | Entrez:608 MIM:109545 HGNC:HGNC:11913 Ensembl:ENSG00000048462 AllianceGenome:HGNC:11913 | |
| Description | TNF receptor superfamily member 17 | |||||
| GTO ID | GTC3610 |
| Trial ID | NCT06067581 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | SENL103 |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Clinical Study on the Safety and Efficacy of SENL103 Autologous T Cell Injection in the Treatment of Recurrent or Refractory Plasma Cell Blood Tumors |
| Year | 2023 |
| Country | China |
| Company sponsor | Hebei Senlang Biotechnology Inc., Ltd. |
| Other ID(s) | SENL103 CAR-T |
| Cohort 1 | |||||||||||
|
|||||||||||